膦甲酸钠治疗血液病患者合并EB病毒感染的临床疗效

doi:10.6040/j.issn.1671-7554.0.2016.1024

摘要/Abstract

摘要： 目的探讨膦甲酸钠治疗血液病合并EBV感染患者,改善患者EBV血症的临床疗效、安全性及临床意义。方法回顾性分析2014年1月至2015年10月收治的血液病合并EBV感染患者112例,其中男70例,女42例,分为恶性血液病组(n=94例)和非恶性血液病组(n=18例),根据有无巨细胞病毒(CMV)感染以及是否接受骨髓移植治疗,恶性血液病组分为单纯EBV感染和合并CMV感染组,化疗组和骨髓移植组。以上患者均给予膦甲酸钠,60 mg/(kg·d),每12 h给药,每次静脉滴注至少3 h;疗程14 d,每周复查血常规、EBV病毒DNA定量和肝肾功,评价其治疗效果及不良反应。结果应用膦甲酸钠治疗血液病合并EBV感染患者总有效率72.3%,其中恶性血液病组有效率72.3%,非恶性血液病组有效率72.2%。两组差异无统计学意义(P>0.05)。采用非参数秩和检验进行不同年龄、性别之间的疗效比较,各组差异无统计学意义(P>0.05)。在恶性血液病组中,合并CMV感染组疗效比单纯EBV感染组好,差异有统计学意义(P<0.05),而化疗组和骨髓移植组相比疗效差异无统计学意义(P>0.05)。治疗后各组患者EBV的DNA拷贝数有不同程度下降,用药达到有效中位时间为10.3~14.5 d。不良反应主要有恶心、心慌等症状,均可耐受。结论膦甲酸钠治疗血液病患者的EBV感染具有较好的有效性,不良反应较少,安全可耐受。

关键词: 膦甲酸钠, EBV感染, 血液病, 疗效

Abstract: Objective To investigate the efficacy of foscarnet in the treatment of hematonosis plus Epstein-barr virus(EBV)infection. Methods The clinical data of 112 cases of hematonosis complicated with EBV infection treated during Jan. 2014 and Oct. 2015 were retrospectively analyzed, including 70 males and 42 females. The patients were divided into malignant group(n=84)and non-malignant group(n=18). Based on the presence of cytomegalovirus(CMV)infection and bone marrow transplantation, the malignant group was subdivided into 4 groups: simple EBV group, EBV plus CMV group, chemotherapy group, and bone marrow transplantation group. All patients were given 山东大学学报 (医学版)55卷9期 -赵文博,等.膦甲酸钠治疗血液病患者合并EB病毒感染的临床疗效 \=-foscarnet 60 mg/kg per 12 hours for 14 days. Peripheral blood samples were collected weekly for blood routine test, DNA quantity of EBV and liver-kidney function analysis, to evaluate the effect and adverse reactions of the treatment. Results The total effective rate was 72.3%, which was 72.3% and 72.2% respectively for the malignant group and non-malignant group, with no statistical difference(P>0.05). There was no statistically significant difference in the effective rate between male and female groups and different age groups(P>0.05). In the malignant group, EBV plus CMV group had higher effective rate than the simple EBV group, with statistically significant difference(P<0.05), while there was no difference between the chemotherapy group and bone marrow transplantation group(P>0.05). The copies of DNA of EBV decreased after treatment. The median time for effectiveness was 10.3 to 14.5 days. Adverse reactions such as nausea and palpitation were observed, but all were tolerable. Conclusion Foscarnet is safe and effective in the treatment of EBV infection in patients with malignant hematonosis, with a few tolerable adverse reactions.

Key words: Foscarnet, Epstein-Barr virus infection, Hematonosis, Therapeutic effect

中图分类号:

R711

赵文博,甄长青,袁代,单宁宁,王娜,封丽丽,李沛沛,丁梅,李英,张凌岩,王欣. 膦甲酸钠治疗血液病患者合并EB病毒感染的临床疗效[J]. 山东大学学报（医学版）, 2017, 55(9): 96-99.

ZHAO Wenbo, ZHEN Changqing, YUAN Dai, SHAN Ningning, WANG Na, FENG Lili, LI Peipei, DING Mei, LI Ying, ZHANG Lingyan, WANG Xin. Efficacy and safety of foscarnet in the treatment of hematonosis complicated with Epstein-barr virus infection[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 96-99.

参考文献

[1] Rafailidis PI, Mavros MN, Kapaskelis A, et al. Antiviral treatment for severe EBV infections in apparently immunocompetent patients[J]. J Clin Virol, 2010, 49(3): 151-157.
[2] 桂瑞瑞, 周健, 张艳莉, 等. EB病毒感染与恶性血液病相关性研究[J]. 中华实验和临床感染病杂志, 2012, 6(3): 16-18. GUI Ruirui, ZHOU Jian, ZHANG Yanli, et al. Association between Epstein-Barr virus infection and malignant hematologic diseases[J]. Chinese Journal of Experimental and Clinical Infectious Disease, 2012, 6(3): 16-18.
[3] Xuan L, Huang F, Fan Z, et al. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies[J]. J Hematol Oncol, 2012, 5(1): 46.
[4] Sanz J, Arango M, Senent L, et al. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases[J]. Bone Marrow Transplant, 2014, 49(3): 397-402.
[5] 韩婷婷, 许兰平, 刘代红, 等. 异基因造血干细胞移植后EB病毒感染情况分析[J]. 中华血液学杂志, 2013, 34(8): 651-654. HAN Tingting, XU Lanping, LIU Daihong, et al. Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation[J]. Chinese Journal of Hematology, 2013, 34(8): 651-654.
[6] Rafailidis PI, Mavros MN, Kapaskelis A, et al. Antiviral treatment for severe EBV infections in apparently immunocompetent patients[J]. J Clin Virol, 2010, 49(3): 151-157.
[7] Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens[J]. Brit J Haematol, 2013, 162(3): 376-382.
[8] Petropoulou AD, Porcher R, Peffault de Latour R, et al. Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation[J]. Transplantation, 2012, 94(8): 879-883.
[9] Fernández-Ruiz M, San-Juan R, Aguado JM. Epstein-Barr virus DNAemia and infectious complications after preemptive rituximab treatment[J]. Transplantation, 2013, 95(3): 13.
[10] Raymund RR. Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus[J]. Mayo Clin Proc, 2011, 86(10): 1009-1026.
[11] Coen DM, Schaffer PA. Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets[J]. Nat Rev Drug Discov, 2003(2): 278-288.
[12] Bacigalupo A, Boyd A, Slipper J, et al. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients[J]. Expert Rev Anti Infect Ther, 2012, 10(11): 1249-1264.
[13] Schneider U, Ruhnke M, Delecluse HJ, et al. Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet[J]. Ann Hematol, 2000, 79(4): 214-216.
[14] Oertel SH, Riess H. Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations[J]. Recent Results Cancer Res, 2002, 159(159): 89-95.
[15] Ai Sato, Naoya Nakamura, Minoru Kojima, et al. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era[J]. Cancer Sci, 2014, 105(9): 1170-1175.

相关文章 15

[1]	王兴山,张浩天,张云峰,周一新. 旋转铰链膝在复杂初次膝关节置换中的应用及临床疗效[J]. 山东大学学报 (医学版), 2026, 64(4): 51-57.
[2]	罗淇,王霞,姜孟. 脑功能网络分析在失语症诊疗中的应用:病理机制分析、临床诊断与疗效评价[J]. 山东大学学报 (医学版), 2025, 63(8): 111-126.
[3]	苗壮,刘培来. 双柱活动平台单髁假体治疗膝关节前内侧骨关节炎的中期疗效[J]. 山东大学学报 (医学版), 2025, 63(7): 62-67.
[4]	国科,陈绪军,郑宝石,施超,黄克力,曹勇,陈军,吴东凯,张晓慎,罗俊辉,申林,莫绪明,杨岷,王晓武,雷印胜,田茂州,王振东,孟自力,孙忠东,李有金,陆辉辉,孟春营,高峰,陈黔苏,郭能瑞,柳德斌,张楠,林宇,陈文生,宋保国,方智,王海晨,廖晓波,徐朝军. 快通道拔管在全动脉冠脉旁路移植术的多中心临床效果[J]. 山东大学学报 (医学版), 2025, 63(5): 26-32.
[5]	王建旭,彭晓辉,丰浩田,安森博,董恣豪,黄子帅,刘喆,杨光. 应用内支撑技术辅助膝关节前交叉韧带全内重建术近期疗效观察[J]. 山东大学学报 (医学版), 2025, 63(3): 22-27.
[6]	贾振存,吴晨睿,赵德龙,朱可嘉,丁森泰. 八宝丹胶囊联合米拉贝隆治疗女性膀胱过度活动症的有效性与安全性[J]. 山东大学学报 (医学版), 2025, 63(10): 72-79.
[7]	孙晓丹,杨创. 多黏菌素B治疗ICU耐碳青霉烯类革兰阴性杆菌感染患者的效果[J]. 山东大学学报 (医学版), 2024, 62(7): 72-77.
[8]	冯绪强,高萍,孙超,陶琳,闫根全,冷冰. 替加环素治疗感染性疾病临床疗效及影响因素[J]. 山东大学学报 (医学版), 2024, 62(12): 11-20.
[9]	吴磊丽,蔡华丽,孙德胜,魏蔚霞. 超声引导穿刺硬化术联合地诺孕素治疗卵巢子宫内膜异位囊肿的疗效[J]. 山东大学学报 (医学版), 2023, 61(6): 65-69.
[10]	邵长秀,贺青卿,庄晓璇,周鹏,李小磊,岳涛,徐婧,李陈钰,郭浩男,庄大勇. 甲状旁腺全切加微量腺体自体移植术治疗109例肾性继发性甲状旁腺功能亢进的长期疗效[J]. 山东大学学报 (医学版), 2023, 61(4): 42-48.
[11]	杨晓斐,韩波,姜殿东,吕建利,伊迎春,张建军,赵立健,王静,王艳,袁辉. 经导管射频消融术治疗儿童快速性心律失常972例临床分析[J]. 山东大学学报 (医学版), 2023, 61(2): 49-56.
[12]	王成,张淑卉,闫娜,孟林林,陈良志,刘庆华. 脐带间充质干细胞治疗中晚期博来霉素诱导小鼠肺间质纤维化的机制[J]. 山东大学学报 (医学版), 2023, 61(10): 17-22.
[13]	巨艳丽,王丽华,成芳,黄凤艳,陈学禹,贾红英. 基于机器学习构建放射性碘治疗疗效的预测模型[J]. 山东大学学报 (医学版), 2023, 61(1): 94-99.
[14]	孙继业,王紫欧,孙晓伟,李洪涛. 中药熏蒸联合体外冲击波对72例髋关节撞击综合征临床疗效、血清炎症因子水平的影响[J]. 山东大学学报 (医学版), 2022, 60(4): 76-81.
[15]	李青,林雪艳,刘天航,李晓文,范明喆,赵瑞瑞,田永杰. 经阴道网片盆底重建术的疗效中长期随访[J]. 山东大学学报 (医学版), 2022, 60(3): 71-75.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed